1423077-10-4

Basic information

• Product Name: N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-4-methylbenzenesulfonamide
• Synonyms: N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-4-methylbenzenesulfonamide
• CAS NO: 1423077-10-4
• Molecular Weight: 440.994
• Mol File: 1423077-10-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-4-methylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-4-methylbenzenesulfonamide(1423077-10-4)
• EPA Substance Registry System: N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-4-methylbenzenesulfonamide(1423077-10-4)

Safety Data

• Hazardous Substances Data: 1423077-10-4(Hazardous Substances Data)

Upstream product

• 1423077-06-8 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-3-oxopropanenitrile 
• 32943-25-2 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine 
• 726140-60-9 2-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethanone 
• 98-59-9 p-toluenesulfonyl chloride 
• 62724-32-7 Didemethylclomipramine 
• 1423077-08-0 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-amine hydrochloride 

Relevant articles and documents

Reengineered tricyclic anti-cancer agents

The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.